Table 1. Clinical variables specific to subtypes.
S-1, subtype 1; S-2, subtype 2; S-3, subtype 3; BMI, body mass index.
| (A) Clinical variables significantly specific to T2D subtype 1
| |||||||
|---|---|---|---|---|---|---|---|
| Clinical variables | Mean or % subtype 1 | Mean or % subtype 2 | Mean or % subtype 3 | P (1 versus 2 + 3) | S-1 | S-2 | S-3 |
| Platelet count (109/liter) | 98.36 ± 17.86 | 228.24 ± 2.90 | 228.61 ± 2.45 | <0.0001 | Y | ||
| Urine protein concentration (mg/dl) | 51.19 ± 14.38 | 152.67 ± 37.21 | 219.98 ± 47.62 | 0.0001 | Y | ||
| Lactate dehydrogenase (U/liter) | 193.35 ± 8.88 | 231.03 ± 8.82 | 251.34 ± 8.17 | <0.0001 | Y | ||
| Age (years) | 59.76 ± 0.45 | 64.25 ± 0.50 | 63.65 ± 0.38 | <0.0001 | Y | ||
| Blood urea nitrogen (mg/dl) | 16.69 ± 0.35 | 19.38 ± 0.59 | 19.52 ± 0.35 | <0.0001 | Y | ||
| Neutrophil count (109/liter) | 2.50 ± 0.58 | 4.78 ± 0.12 | 4.83 ± 0.09 | 0.0024 | Y | ||
| White blood cell count (109/liter) | 5.32 ± 0.57 | 7.28 ± 0.09 | 7.46 ± 0.07 | 0.001 | Y | ||
| Respirations | 16.65 ± 0.16 | 17.50 ± 0.14 | 17.62 ± 0.08 | <0.0001 | Y | ||
| Urine protein-to-creatinine ratio | 0.40 ± 0.09 | 1.19 ± 0.26 | 2.48 ± 0.45 | <0.0001 | Y | Y | |
| Serum creatinine (mg/dl) | 1.00 ± 0.02 | 1.25 ± 0.07 | 1.27 ± 0.04 | <0.0001 | Y | ||
| Eosinophil count (109/liter) | 0.09 ± 0.02 | 0.19 ± 0.01 | 0.20 ± 0.01 | 0.0003 | Y | ||
| Blood protein total (g/dl) | 7.49 ± 0.03 | 7.34 ± 0.04 | 7.14 ± 0.03 | <0.0001 | Y | Y | |
| Serum albumin (g/dl) | 4.27 ± 0.02 | 4.03 ± 0.03 | 4.04 ± 0.02 | <0.0001 | Y | ||
| Serum calcium (mg/dl) | 9.90 ± 0.02 | 9.66 ± 0.03 | 9.60 ± 0.02 | <0.0001 | Y | ||
| CO2 total | 26.60 ± 0.13 | 26.05 ± 0.15 | 26.16 ± 0.09 | 0.0011 | Y | ||
| Mean platelet volume (fl) | 9.97 ± 0.37 | 8.98 ± 0.05 | 8.97 ± 0.04 | 0.008 | Y | ||
| Prothrombin time* (s) | 29.18 ± 3.64 | 14.10 ± 0.33 | 14.13 ± 0.27 | 0.0005 | Y | ||
| INR* | 2.57 ± 0.34 | 1.19 ± 0.03 | 9.32 ± 0.41 | 0.0005 | Y | ||
| BMI | 33.07 ± 0.29 | 31.32 ± 0.30 | 31.19 ± 0.02 | <0.0001 | Y | ||
| Estimated GFR calculation (MDRD, ml/min/1.73 m2) | 74.86 ± 1.47 | 68.40 ± 1.99 | 65.04 ± 1.33 | <0.0001 | Y | ||
| GFR estimate (ml/min/1.73 m2) | 72.26 ± 1.47 | 64.62 ± 1.77 | 63.75 ± 1.22 | <0.0001 | Y | ||
| Glucose* (mg/dl) | 193.69 ± 11.45 | 149.55 ± 4.18 | 158.69 ± 2.90 | 0.0005 | Y | ||
| Insulin | 21.92% | 29.82% | 45.16% | <0.0001 | Y | Y | Y |
| Metformin | 6.43% | 23.01% | 21.17% | <0.0001 | Y | ||
| Loop diuretics | 5.51% | 14.10% | 18.34% | <0.0001 | Y | ||
| DPP4 | 1.05% | 6.48% | 6.39% | <0.0001 | Y | ||
| CCBs | 19.55% | 30.63% | 35.31% | <0.0001 | Y | ||
| β-Blocker | 21.92% | 39.06% | 45.80% | <0.0001 | Y | Y | |
| ARB/ACEI | 48.16% | 57.05% | 62.96% | <0.0001 | Y | Y | |
| Vasodilators | 0.92% | 5.02% | 5.57% | <0.0001 | Y | ||
| Nicotinic acid derivatives | 0.13% | 1.30% | 1.37% | 0.02 | Y | ||
| (B) Clinical variables significantly specific to T2D subtype 2
| |||||||
|---|---|---|---|---|---|---|---|
| Clinical variable | Mean or % subtype 1 | Mean or % subtype 2 | Mean or % subtype 3 | P (2 versus 1 + 3) | S-1 | S-2 | S-3 |
| Weight (kg) | 92.26 ± 1.08 | 85.17 ± 1.14 | 89.16 ± 0.83 | <0.0001 | Y | ||
| Troponin I level (ng/ml) | 0 | 0.03 ± 0.01 | 0.36 ± 0.09 | 0.0003 | Y | Y | |
| Insulin | 21.92% | 29.82% | 45.16% | <0.0001 | Y | Y | Y |
| (C) Clinical variables significantly specific to T2D subtype 3
| |||||||
|---|---|---|---|---|---|---|---|
| Clinical variable | Mean or % subtype 1 | Mean or % subtype 2 | Mean or % subtype 3 | P (3 versus 1 + 2) | S-1 | S-2 | S-3 |
| Blood protein total (g/dl) | 7.49 ± 0.03 | 7.34 ± 0.04 | 7.14 ± 0.03 | 0 | Y | Y | |
| Urine protein-to-creatinine ratio | 0.40 ± 0.09 | 1.19 ± 0.26 | 2.48 ± 0.45 | 0.0006 | Y | Y | |
| Troponin I level (ng/ml) | 0 | 0.03 ± 0.01 | 0.36 ± 0.09 | 0.0003 | Y | Y | |
| Systolic blood pressure (mmHg) | 132.04 ± 0.73 | 132.41 ± 0.92 | 135.7 ± 0.7 | 0.0001 | Y | ||
| Serum chloride level (mEq/liter) | 101.01 ± 0.17 | 101.45 ± 0.18 | 102.03 ± 0.11 | 0 | Y | ||
| HMG-CoA reductase inhibitors (statins) | 42.26% | 45.71% | 56.39% | <0.0001 | Y | ||
| Centrally acting antihypertensives | 1.44% | 1.30% | 4.11% | 0.0001 | Y | ||
| ARB/ACEI | 48.16% | 57.05% | 62.96% | <0.0001 | Y | Y | |
| β-Blocker | 21.92% | 39.06% | 45.80% | <0.0001 | Y | Y | |
| Insulin | 21.92% | 29.82% | 45.16% | <0.0001 | Y | Y | Y |
*
Point of care.